Question Everything. See who's reporting it.

Symbiotec Pharmalab Demands P/E of 58 Amid API Dominance

Source: Economic Times

The story in brief

Symbiotec Pharmalab, the only company with a presence across the top 10 corticosteroid and steroidal-hormone APIs in FY26, demands a P/E multiple of up to 58 based on its post-IPO equity and net profit. APIs account for over 96% of revenue, with new initiatives like complex injectables and CDMO offerings contributing the rest. The company operates two API facilities and has expanded fermentation capacity to 700 KL.

NEWXFree on Android and iPhone. Open in NEWX